What does this research mean for the field?

Developing trispecific CAR-T therapies for B-cell malignancies involves overcoming significant immunological challenges, including the organism's natural self-tolerance mechanisms. Novelty: ClaimNovelty.SYNTHESIS. Consensus alignment: ConsensusAlignment.NEUTRAL.

October 28, 2025Expert Opinion on Biological Therapy1 citationsOpen Access

View Full Paper

Challenges and considerations in developing trispecific CAR-Ts for B-cell malignancies

UKUday KulkarniKLE Technological University MLMarcos de LimaCleveland State University BDBoro DropulićHeat Biologics (United States)

Key Points

Key points are not available for this paper at this time.

Abstract

At the beginning of the 20th century, Paul Ehrlich coined the term “horror autotoxicus” for the unwillingness of the organism to develop an immune attack on its own cells (1) which we now refer ...

问 AI

Bookmark

View Full Paper

问 AI

Bookmark

View Full Paper

Challenges and considerations in developing trispecific CAR-Ts for B-cell malignancies

Key Points

Abstract

Cite This Study

Also Consider

Also Consider